CD3 and FcRH5

This usually refers to a bispecific therapeutic approach where an antibody or a cell therapy is engineered to simultaneously bind CD3 (on T-cells) and FcRH5 (on malignant plasma cells), promoting immune synapse formation and targeted killing of cancer cells such as in multiple myeloma. CD3 is a multi-subunit signaling component of the T-cell receptor complex, critical for T-cell activation. FcRH5 is a transmembrane receptor predominantly expressed on B-cell lineage cells, especially in multiple myeloma, making it a promising therapeutic target.

Other names

CD3 epsilonT-cell surface glycoprotein CD3 epsilon chainT3ECD3EFcRL5IRTA2CD307CD3/FcRH5 bispecific target

Simultaneous engagement of CD3 on T-cells and FcRH5 on malignant plasma cells brings them into close proximity, induces immune synapse formation, triggers TCR signaling, and leads to targeted cell killing primarily via T-cell mediated cytotoxicity (including granzyme/perforin release).